Free Trial

Salarius Pharmaceuticals (SLRX) Competitors

Salarius Pharmaceuticals logo
$4.58 -0.06 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$4.64 +0.06 (+1.42%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLRX vs. ALBT, ERNA, INAB, APRE, DWTX, ADXN, APM, KPRX, PCSA, and RNAZ

Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Avalon GloboCare (ALBT), Ernexa Therapeutics (ERNA), IN8bio (INAB), Aprea Therapeutics (APRE), Dogwood Therapeutics (DWTX), Addex Therapeutics (ADXN), Aptorum Group (APM), Kiora Pharmaceuticals (KPRX), Heatwurx (PCSA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

Salarius Pharmaceuticals vs. Its Competitors

Salarius Pharmaceuticals (NASDAQ:SLRX) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Avalon GloboCare. MarketBeat recorded 5 mentions for Salarius Pharmaceuticals and 2 mentions for Avalon GloboCare. Salarius Pharmaceuticals' average media sentiment score of 0.50 beat Avalon GloboCare's score of 0.49 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Salarius Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avalon GloboCare
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Salarius Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Salarius PharmaceuticalsN/A -556.47% -192.35%
Avalon GloboCare -1,451.94%N/A -75.12%

Salarius Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Salarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.11
Avalon GloboCare$1.33M7.22-$7.90M-$19.96-0.13

Salarius Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500.

11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 1.2% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Salarius Pharmaceuticals beats Avalon GloboCare on 6 of the 11 factors compared between the two stocks.

Get Salarius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLRX vs. The Competition

MetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.37M$2.64B$5.78B$10.04B
Dividend YieldN/A49.23%5.27%4.52%
P/E RatioN/A23.7475.5726.08
Price / SalesN/A501.55516.51171.66
Price / CashN/A167.9837.2059.76
Price / Book0.325.2711.536.20
Net Income-$5.58M$32.95M$3.29B$270.65M
7 Day Performance-4.58%1.34%0.44%2.77%
1 Month Performance-38.93%30.71%10.84%8.83%
1 Year Performance-79.09%2.03%61.62%27.49%

Salarius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRX
Salarius Pharmaceuticals
0.7049 of 5 stars
$4.58
-1.3%
N/A-79.5%$2.37MN/A0.0020News Coverage
ALBT
Avalon GloboCare
1.5842 of 5 stars
$2.51
+6.4%
N/A-54.5%$9.64M$1.33M-0.135
ERNA
Ernexa Therapeutics
0.4736 of 5 stars
$1.26
+1.2%
N/A-94.6%$9.63M$580K-0.1510News Coverage
Positive News
Short Interest ↓
Gap Up
INAB
IN8bio
2.8452 of 5 stars
$2.06
-4.6%
$180.00
+8,637.9%
-78.0%$9.35MN/A-0.2320Positive News
Short Interest ↓
APRE
Aprea Therapeutics
2.1995 of 5 stars
$1.60
-0.4%
$15.50
+866.3%
-53.0%$9.35M$1.50M-0.697
DWTX
Dogwood Therapeutics
1.0381 of 5 stars
$4.87
-0.6%
$10.00
+105.3%
N/A$9.31MN/A-0.265Positive News
ADXN
Addex Therapeutics
1.5735 of 5 stars
$8.70
+7.5%
$30.00
+245.0%
-25.5%$9.22M$460K-25.5830Gap Down
APM
Aptorum Group
1.8934 of 5 stars
$1.72
+0.6%
N/A-41.6%$9.20M$430K0.0030
KPRX
Kiora Pharmaceuticals
2.8775 of 5 stars
$2.65
-1.7%
$10.00
+278.1%
-23.3%$9.07M$16.02M-0.9110Positive News
PCSA
Heatwurx
3.1238 of 5 stars
$0.18
-3.0%
$1.00
+465.0%
-86.5%$8.91MN/A-0.0820Short Interest ↑
RNAZ
TransCode Therapeutics
1.6164 of 5 stars
$10.73
-1.2%
$280.00
+2,509.5%
-99.9%$8.91MN/A0.009Short Interest ↓
Gap Up

Related Companies and Tools


This page (NASDAQ:SLRX) was last updated on 9/10/2025 by MarketBeat.com Staff
From Our Partners